Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00673_DB01285 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00673_DB01285 label "DDI between Aprepitant and Corticotropin - Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. [drugbank_resource:DB00673_DB01285]" assertion.
- drugbank_resource:DB00673_DB01285 identifier "drugbank_resource:DB00673_DB01285" assertion.
- drugbank_resource:DB00673_DB01285 title "DDI between Aprepitant and Corticotropin - Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen." assertion.
- drugbank:DB00673 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00673_DB01285 assertion.
- drugbank:DB01285 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00673_DB01285 assertion.